EARLY DATA FROM A PHASE I STUDY OF NINTEDANIB (BIBF 1120) IN ASIAN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Yen, C. [1 ]
Shen, Y. [2 ]
Shiah, H. [3 ]
Chen, J. [2 ]
Hsu, C. [2 ]
Hsu, C. [2 ]
Huang, D. C. [4 ]
Hocke, J. [5 ]
Su, W. [1 ]
Cheng, A. [2 ]
机构：
[1] Natl Cheng Kung Univ, Coll Med & Hosp, Tainan 70101, Taiwan
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Natl Hlth Res Inst, Tainan, Taiwan
[4] Boehringer Ingelheim Taiwan Ltd, Oncol, Taipei, Taiwan
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Oncol, Biberach, Germany
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：246 / 247
页数：2
相关论文
共 50 条
  • [31] A RANDOMISED PHASE II STUDY OF NINTEDANIB (BIBF1120) COMPARED TO CHEMOTHERAPY IN PATIENTS WITH RECURRENT CLEAR CELL CARCINOMA OF THE OVARY OR ENDOMETRIUM. (NICCC/ENGOT-OV36)
    Glasspool, Rosalind
    Mcneish, Iain
    Westermann, Anneke
    Hinsley, Samantha
    Ledermann, Jonathan
    Ray-Coquard, Isabelle
    Lawless, Claire
    Ottevanger, Nelleke
    Mirza, Mansoor Raza
    Alexandre, Jerome
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A127 - A128
  • [32] Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
    Okamoto, Isamu
    Miyazaki, Masaki
    Takeda, Masayuki
    Terashima, Masaaki
    Azuma, Koichi
    Hayashi, Hidetoshi
    Kaneda, Hiroyasu
    Kurata, Takayasu
    Tsurutani, Junji
    Seto, Takashi
    Hirai, Fumihiko
    Konishi, Koichi
    Sarashina, Akiko
    Yagi, Nobutaka
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 346 - 352
  • [33] A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients (pts).
    Prenen, H.
    D'Haens, G.
    Capdevila, J.
    Carreto, A.
    Sobrero, A.
    Ducreux, M.
    Francois, E.
    Staines, H.
    Amella, N.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
    Gordon, Sarah W.
    McGuire, William P., III
    Shafer, Danielle A.
    Sterling, Richard K.
    Lee, Hannah M.
    Matherly, Scott C.
    Roberts, John D.
    Bose, Prithviraj
    Tombes, Mary B.
    Shrader, E. Ellen
    Ryan, Alison A.
    Kmieciak, Maciej
    Tri Nguyen
    Deng, Xiaoyan
    Bandyopadhyay, Dipankar
    Dent, Paul
    Poklepovic, Andrew S.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (08): : 649 - 654
  • [35] Phase I Study of Sorafenib and SBRT for Advanced Hepatocellular Carcinoma
    Dawson, L. A.
    Brade, A.
    Cho, C.
    Kim, J.
    Brierley, J.
    Dinniwell, R.
    Wong, R.
    Ringash, J.
    Cummings, B.
    Knox, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S10 - S11
  • [36] A phase I study of ganetespib in advanced hepatocellular carcinoma (HCC)
    Goyal, Lipika
    Wadlow, Raymond Couric
    Blaszkowsky, Lawrence Scott
    Wolpin, Brian M.
    Vasudev, Eamala
    Sheehan, Susan
    Knowles, Michelle
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    Finn, Richard S.
    Poon, Ronnie T. P.
    Yau, Thomas
    Klumpen, Heinz-Josef
    Chen, Li-Tzong
    Kang, Yoon-Koo
    Kim, Tae-You
    Gomez-Martin, Carlos
    Rodriguez-Lope, Carlos
    Kunz, Tiffany
    Paquet, Thierry
    Brandt, Ulrike
    Sellami, Dalila
    Bruix, Jordi
    JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1271 - 1277
  • [38] Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Finn, R. S.
    Poon, R. T. P.
    Yau, T.
    Klumpen, H.
    Chen, L.
    Kang, Y.
    Kim, T.
    Gomez-Martin, C.
    Rodriguez-Lope, C.
    Kunz, T.
    Paquet, T.
    Asubonteng, K.
    Winkler, R. E.
    Anak, O.
    Sellami, D. B.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium.
    Glasspool, Rosalind Margaret
    McNeish, Iain A.
    Paul, James
    Lawless, Claire A.
    Taggart, Diann
    Millan, David W. M.
    McCluggage, W. Glenn
    Wilkinson, Nafisa
    Barlow, Clare Stephanie
    Hall, Geoff
    Waters, Justin S.
    Banerjee, Susana N.
    Alexandre, Jerome
    Fur, Nathalie L. E.
    Westermann, A. M.
    Coens, Corneel
    Jederud, Christina
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    du Bois, A.
    Huober, J.
    Stopfer, P.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Reichardt, V. L.
    Harter, P.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 370 - 375
12345